Over the past 15 years, subgroups of LUAD have been identified by using oncogenic drivers, such as the gene encoding epidermal growth factor receptor (EGFR), resulting in breakthroughs for the treatment of non-small-cell lung cancer (NSCLC) [1]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.